Inventor
BOURNE GREGORY THOMAS
AU15 patents
⚠️ This page may combine multiple inventors who share the name “BOURNE GREGORY THOMAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PROTAGONIST THERAPEUTICS INC
13 patentsUS9624268B2Apr 18, 2017
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PROTAGONIST THERAPEUTICS INC40 citations97
US9822157B2Nov 21, 2017
Hepcidin analogues and uses thereof
PROTAGONIST THERAPEUTICS INC35 citations95
US10941183B2Mar 9, 2021
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PROTAGONIST THERAPEUTICS INC13 citations94
US10278957B2May 7, 2019
Opioid agonist peptides and uses thereof
PROTAGONIST THERAPEUTICS INC16 citations94
US10501515B2Dec 10, 2019
Hepcidin analogues and uses thereof
PROTAGONIST THERAPEUTICS INC18 citations93
US10442846B2Oct 15, 2019
Hepcidin analogues and uses thereof
PROTAGONIST THERAPEUTICS INC19 citations93
US10729676B2Aug 4, 2020
Opioid agonist peptides and uses thereof
PROTAGONIST THERAPEUTICS INC10 citations83
US11472842B2Oct 18, 2022
Analogues of hepcidin mimetics with improved in vivo half lives
PROTAGONIST THERAPEUTICS INC5 citations72
US11807674B2Nov 7, 2023
Hepcidin analogues and uses thereof
PROTAGONIST THERAPEUTICS INC3 citations71
US11753443B2Sep 12, 2023
Conjugated hepcidin mimetics
PROTAGONIST THERAPEUTICS INC3 citations70
US11884748B2Jan 30, 2024
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PROTAGONIST THERAPEUTICS INC0 citations62
US12269856B2Apr 8, 2025
Hepcidin analogues and uses thereof
PROTAGONIST THERAPEUTICS INC0 citations61
US12234300B2Feb 25, 2025
Conjugated hepcidin mimetics
PROTAGONIST THERAPEUTICS INC0 citations59